Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLLSNASDAQ:FNCHNASDAQ:OCXNASDAQ:PLRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLLSCellectis$1.41-3.4%$1.42$1.10▼$2.81$78.37M3.11142,784 shs39,491 shsFNCHFinch Therapeutics Group$13.70+5.4%$13.23$0.80▼$15.85$22.00M1.272,297 shs830 shsOCXOncoCyte$3.33+2.5%$2.99$1.92▼$4.75$95.24M0.9558,050 shs37,955 shsPLRXPliant Therapeutics$1.35+5.5%$1.42$1.10▼$16.10$82.87M1.431.10 million shs1.01 million shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLLSCellectis-0.68%-5.19%-4.58%+4.29%-48.23%FNCHFinch Therapeutics Group+5.38%+0.74%+8.73%-13.18%+661.11%OCXOncoCyte-3.56%+10.54%-5.52%+26.46%+14.84%PLRXPliant Therapeutics-0.78%-6.57%-12.33%-58.97%-89.95%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLLSCellectis3.0675 of 5 stars3.55.00.00.01.82.50.6FNCHFinch Therapeutics GroupN/AN/AN/AN/AN/AN/AN/AN/AOCXOncoCyte2.7163 of 5 stars3.44.00.00.03.50.80.6PLRXPliant Therapeutics4.3721 of 5 stars4.03.00.04.72.61.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLLSCellectis 3.00Buy$6.67372.81% UpsideFNCHFinch Therapeutics Group 0.00N/AN/AN/AOCXOncoCyte 2.75Moderate Buy$6.0682.06% UpsidePLRXPliant Therapeutics 2.00Hold$13.31886.11% UpsideCurrent Analyst Ratings BreakdownLatest FNCH, CLLS, PLRX, and OCX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2025OCXOncoCyteUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.005/21/2025OCXOncoCyteLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$5.00 ➝ $8.005/13/2025CLLSCellectisBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$5.00 ➝ $4.005/13/2025OCXOncoCyteNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.25 ➝ $4.254/8/2025OCXOncoCyteNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.25 ➝ $4.253/28/2025OCXOncoCyteLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$5.003/25/2025OCXOncoCyteStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingEqual Weight ➝ Equal Weight$4.00 ➝ $4.003/25/2025OCXOncoCyteNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.25 ➝ $4.253/18/2025PLRXPliant TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/4/2025PLRXPliant TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$4.00 ➝ $1.503/4/2025PLRXPliant TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLLSCellectis$47.63M1.65N/AN/A$1.52 per share0.93FNCHFinch Therapeutics Group$110K200.02N/AN/A$14.25 per share0.96OCXOncoCyte$3.84M24.78N/AN/A$2.48 per share1.34PLRXPliant Therapeutics$1.58M52.45N/AN/A$7.91 per share0.17Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLLSCellectis-$101.06M-$0.86N/AN/AN/A-234.39%-74.55%-22.65%8/5/2025 (Estimated)FNCHFinch Therapeutics Group-$74.75M-$8.82N/A∞N/AN/A-69.14%-26.92%N/AOCXOncoCyte-$27.78M-$3.53N/AN/AN/A-6,122.29%-269.32%-59.71%8/14/2025 (Estimated)PLRXPliant Therapeutics-$161.34M-$3.61N/AN/AN/AN/A-48.91%-41.09%8/6/2025 (Estimated)Latest FNCH, CLLS, PLRX, and OCX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025CLLSCellectis-$0.1540-$0.18-$0.0260-$0.18$12.71 million$12.03 million5/12/2025Q1 2025OCXOncoCyte-$0.24-$0.26-$0.02-$0.26$0.13 million$2.14 million3/24/2025Q4 2024OCXOncoCyte-$0.40$0.48+$0.88-$1.93$0.16 million$1.49 million3/13/2025Q4 2024CLLSCellectis$0.06-$0.16-$0.22-$0.15$5.90 million$33.22 million3/3/2025Q4 2024PLRXPliant Therapeutics-$0.99-$0.82+$0.17-$0.82$0.08 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLLSCellectisN/AN/AN/AN/AN/AFNCHFinch Therapeutics GroupN/AN/AN/AN/AN/AOCXOncoCyteN/AN/AN/AN/AN/APLRXPliant TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLLSCellectis0.481.781.78FNCHFinch Therapeutics GroupN/A3.873.87OCXOncoCyteN/A0.530.50PLRXPliant Therapeutics0.0910.2610.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLLSCellectis63.90%FNCHFinch Therapeutics Group21.77%OCXOncoCyte55.35%PLRXPliant Therapeutics97.30%Insider OwnershipCompanyInsider OwnershipCLLSCellectis16.41%FNCHFinch Therapeutics Group44.90%OCXOncoCyte2.05%PLRXPliant Therapeutics8.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLLSCellectis29055.58 million46.46 millionOptionableFNCHFinch Therapeutics Group1901.61 million885,000No DataOCXOncoCyte12028.60 million17.18 millionNo DataPLRXPliant Therapeutics9061.39 million56.96 millionOptionableFNCH, CLLS, PLRX, and OCX HeadlinesRecent News About These CompaniesPliant Therapeutics, Inc. (NASDAQ:PLRX) Receives $13.31 Average Price Target from BrokeragesMay 25 at 2:37 AM | americanbankingnews.comPliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Rating of "Hold" by AnalystsMay 24, 2025 | marketbeat.comPliant Therapeutics presents new fibrosis treatment dataMay 23, 2025 | investing.comFrazier Life Sciences Management L.P. Makes New Investment in Pliant Therapeutics, Inc. (NASDAQ:PLRX)May 23, 2025 | marketbeat.comPliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International ConferenceMay 21, 2025 | finance.yahoo.comPliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International ConferenceMay 21, 2025 | globenewswire.comDeutsche Bank AG Buys 1,017,500 Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX)May 16, 2025 | marketbeat.comGranahan Investment Management LLC Has $6.94 Million Stock Holdings in Pliant Therapeutics, Inc. (NASDAQ:PLRX)May 12, 2025 | marketbeat.comPliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial ResultsMay 8, 2025 | globenewswire.comBarclays PLC Lowers Stock Holdings in Pliant Therapeutics, Inc. (NASDAQ:PLRX)May 6, 2025 | marketbeat.comPliant Therapeutics announces workforce reductionMay 3, 2025 | uk.investing.comPliant Therapeutics Announces Workforce Reduction and Cost Saving Initiatives to Support Late-Stage Clinical TrialsMay 3, 2025 | nasdaq.comBay Area biotech company Pliant Therapeutics slashes staff after losing $655 million in valueMay 2, 2025 | msn.comPliant Axes 45% of Workforce To Save Cash, Support Late-Stage Clinical TrialsMay 2, 2025 | biospace.comPliant Therapeutics cuts workforce by 45% after bexotegrast trial safety woesMay 2, 2025 | fiercebiotech.comPliant Therapeutics Announces Strategic Realignment of Workforce and OperationsMay 1, 2025 | globenewswire.com649,660 Shares in Pliant Therapeutics, Inc. (NASDAQ:PLRX) Purchased by Adage Capital Partners GP L.L.C.May 1, 2025 | marketbeat.comPrice T Rowe Associates Inc. MD Sells 200,327 Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX)May 1, 2025 | marketbeat.comFirst Light Asset Management LLC Has $22.14 Million Stock Position in Pliant Therapeutics, Inc. (NASDAQ:PLRX)April 30, 2025 | marketbeat.comPliant Therapeutics (PLRX) to Release Quarterly Earnings on MondayApril 30, 2025 | marketbeat.comPliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Rating of "Hold" by BrokeragesApril 28, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFNCH, CLLS, PLRX, and OCX Company DescriptionsCellectis NASDAQ:CLLS$1.41 -0.05 (-3.42%) Closing price 04:00 PM EasternExtended Trading$1.44 +0.03 (+1.77%) As of 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.Finch Therapeutics Group NASDAQ:FNCH$13.70 +0.70 (+5.38%) As of 05/27/2025 03:20 PM EasternFinch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.OncoCyte NASDAQ:OCX$3.33 +0.08 (+2.46%) Closing price 03:59 PM EasternExtended Trading$3.34 +0.00 (+0.15%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.Pliant Therapeutics NASDAQ:PLRX$1.35 +0.07 (+5.47%) Closing price 04:00 PM EasternExtended Trading$1.36 +0.00 (+0.37%) As of 06:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? Qualcomm Stock Turns South: 3 Entry Signals to Watch For D-Wave Quantum Stock: Are Advantage2 Gains Here to Stay? Meta's Institutional & Insider Data Fuels Bulls Despite Disparity Is Michael Burry Right Betting Against the Market Again? Amer Sports: The New ONON and DECK of Consumer Discretionary? BigBear.ai: Risky AI Stock or Defense Tech Opportunity? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.